Differential regulation of TGF-β–induced, ALK-5–mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.

(2017) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma

(2017) David A. Reardon et al.   Journal of the National Comprehensive Cancer Network

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrin control of the transforming growth factor-β pathway in glioblastoma

(2013) Patrick Roth et al.   BRAIN

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

TGF-β – an excellent servant but a bad master

(2012) Lenka Kubiczkova et al.   Journal of Translational Medicine

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

(2012) Pieter J A Eichhorn et al.   NATURE MEDICINE

Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment

(2012) M Weiler et al.   ONCOGENE

Blockade of TGF-  Signaling by the TGF R-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma

(2011) M. Zhang et al.   CANCER RESEARCH

Hypoxia Potentiates Glioma-Mediated Immunosuppression

(2011) Jun Wei et al.   PLoS One

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

(2010) U. Bogdahn et al.   NEURO-ONCOLOGY

Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells

(2009) E. S. Shao et al.   BLOOD

Transforming Growth Factor β Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors

(2009) Katharine H. Wrighton et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

VEGF and inhibitors of TGF  type-I receptor kinase synergistically promote blood-vessel formation by inducing  5-integrin expression

(2009) Z. Liu et al.   JOURNAL OF CELL SCIENCE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Mechanisms of HIF-1α Modulation Induced by Oxygen Tension and BMP2 in Glioblastoma Derived Cells

(2009) Francesca Pistollato et al.   PLoS One

VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells

(2008) Ghazaleh Tabatabai et al.   BRAIN

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL

(2008) Johannes Rieger et al.   JOURNAL OF NEUROCHEMISTRY

Cooperative Assembly of TGF-β Superfamily Signaling Complexes Is Mediated by Two Disparate Mechanisms and Distinct Modes of Receptor Binding

(2008) Jay Groppe et al.   MOLECULAR CELL